CDK4 and cancer: This cohort study found a higher incidence and relative rate for progressive kidney dysfunction for 5015 patients treated with cyclin dependent kinase 4 or 6 (CDK4/6) inhibitors, vascular endothelial growth factor receptor (VEGFR), and epidermal growth factor receptor (EGFR) inhibitors compared with matched controls without cancer.